Literature DB >> 22871696

Genentech's Alzheimer's antibody trial to study disease prevention.

Ken Garber.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22871696     DOI: 10.1038/nbt0812-731

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  22 in total

Review 1.  Central nervous system myeloid cells as drug targets: current status and translational challenges.

Authors:  Knut Biber; Thomas Möller; Erik Boddeke; Marco Prinz
Journal:  Nat Rev Drug Discov       Date:  2015-12-04       Impact factor: 84.694

2.  A noninflammatory immune response in aged DNA Aβ42-immunized mice supports its safety for possible use as immunotherapy in AD patients.

Authors:  Doris Lambracht-Washington; Roger N Rosenberg
Journal:  Neurobiol Aging       Date:  2014-12-12       Impact factor: 4.673

3.  Pivotal trials for β-secretase inhibitors in Alzheimer's.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2015-02       Impact factor: 54.908

4.  Everything but amyloid: new thinking prompts FDA revamp.

Authors:  Eva von Schaper
Journal:  Nat Biotechnol       Date:  2018-06-06       Impact factor: 54.908

5.  Longitudinal thinking.

Authors: 
Journal:  Nat Biotechnol       Date:  2013-03       Impact factor: 54.908

6.  Hope for anti-amyloid antibodies surges, yet again.

Authors:  Chris Morrison
Journal:  Nat Biotechnol       Date:  2016-11-08       Impact factor: 54.908

Review 7.  Leveraging preclinical models for the development of Alzheimer disease therapeutics.

Authors:  Kimberly Scearce-Levie; Pascal E Sanchez; Joseph W Lewcock
Journal:  Nat Rev Drug Discov       Date:  2020-04-08       Impact factor: 84.694

Review 8.  The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes.

Authors:  Valentin K Gribkoff; Leonard K Kaczmarek
Journal:  Neuropharmacology       Date:  2016-03-12       Impact factor: 5.250

Review 9.  Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies.

Authors:  Todd E Golde
Journal:  J Neurochem       Date:  2016-05-04       Impact factor: 5.372

10.  Advances in the development of vaccines for Alzheimer's disease.

Authors:  Doris Lambracht-Washington; Roger N Rosenberg
Journal:  Discov Med       Date:  2013-05       Impact factor: 2.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.